Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 111, Issue 4, Pages 726-727Publisher
WILEY
DOI: 10.1002/cpt.2546
Keywords
-
Categories
Funding
- Arnold Ventures
Ask authors/readers for more resources
The FDA's approval of aducanumab as a treatment for Alzheimer's disease in June 2021 caused significant impact and led to calls for changes to the accelerated approval pathway.
When the US Food and Drug Administration (FDA) approved aducanumab (Aduhelm) as a treatment for Alzheimer's disease in June 2021, it sent shockwaves across the healthcare system for two main reasons: the decision itself and the process leading to the decision. The fallout from this decision in the past year has led to calls for changes to the accelerated approval pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available